The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in hospitalized patients with NERD (non-erosive reflux disease) or GERD (gastroesophageal reflux disease, Los Angeles \[LA\] Grade A-D). During the study, the patients will complete a patient-orientated, self-assessed reflux questionnaire (ReQuest™). The study duration consists of a treatment period of 7 days ± 3 days. Pantoprazole (tablet) will be administered once daily in the morning to patients with NERD or GERD at one dose level for each indication. The study will provide further data on the safety and tolerability of pantoprazole.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
29
Efficacy of Pantoprazole
Nycomed Deutschland GmbH
Augsburg, Germany
Nycomed Deutschland GmbH
Berlin, Germany
Nycomed Deutschland GmbH
Brandenburg, Germany
Nycomed Deutschland GmbH
Cologne, Germany
Nycomed Deutschland GmbH
Cologne, Germany
Nycomed Deutschland GmbH
Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 1 day of treatment
Time frame: 1 day
Symptom reduction from reflux disease related symptoms as measured by the questionnaire ReQuest™-GI (gastrointestinal) after 2 to 7 days of treatment
Time frame: 7 days
Symptom relief rates as measured by ReQuest™ after 7 days of treatment
Time frame: 7 days
Safety
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Erlangen, Germany
Nycomed Deutschland GmbH
Frankfurt, Germany
Nycomed Deutschland GmbH
Frankfurt, Germany
Nycomed Deutschland GmbH
Gera, Germany
Nycomed Deutschland GmbH
Göttingen, Germany
...and 25 more locations